{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:58:22Z","timestamp":1778529502225,"version":"3.51.4"},"reference-count":36,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":141,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Long non-coding RNA (lncRNA) FEZF1 antisense RNA 1 (FEZF1-AS1) has been shown to be up-regulated in tumor tissues and cells, and exerts oncogenic effects on various types of malignancies. However, the expression and function of FEZF1-AS1 was still fully unclear in retinoblastoma. The purpose of our study was to investigate the expression and clinical value of FEZF1-AS1 in retinoblastoma patients, and explore the effect of FEZF1-AS1 on retinoblastoma cell proliferation, migration and invasion. In our results, levels of FEZF1-AS1 expression were elevated in retinoblastoma tissue specimens and cell lines compared with adjacent normal retina tissue specimens and human retinal pigment epithelial cell line, respectively. The correlation analysis indicated that high FEZF1-AS1 expression was significantly correlated with present choroidal invasion and optic nerve invasion. Survival analysis suggested that retinoblastoma patients in high FEZF1-AS1 expression group had obviously short disease-free survival (DFS) compared with retinoblastoma patients in low FEZF1-AS1 expression group, and high FEZF1-AS1 expression was an independent unfavorable prognostic factor for DFS in retinoblastoma patients. Loss-of-function study indicated silencing FEZF1-AS1 expression inhibited retinoblastoma cell proliferation, invasion and migration. In conclusion, FEZF1-AS1 functions as an oncogenic lncRNA in retinoblastoma.<\/jats:p>","DOI":"10.1042\/bsr20190754","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T19:05:10Z","timestamp":1557515110000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["FEZF1-AS1 functions as an oncogenic lncRNA in retinoblastoma"],"prefix":"10.1042","volume":"39","author":[{"given":"Lian-Jiao","family":"Quan","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Qingyang People\u2019s Hospital, Qingyan, Gansu 745000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5217-9151","authenticated-orcid":false,"given":"Wen-Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Xi\u2019an No.4 Hospital, Xi\u2019an, Shaanxi 710004, China"},{"name":"Department of Ophthalmology, Shaanxi Ophthalmic Medical Center, Xi\u2019an, Shaanxi 710004, China"},{"name":"Department of Ophthalmology, Affiliated Guangren Hospital, School of Medicine, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi 710004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"2021111619381175600_B1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1146\/annurev-pathol-012414-040259","article-title":"Genetics and epigenetics of human retinoblastoma","volume":"10","author":"Benavente","year":"2015","journal-title":"Annu. Rev. Pathol."},{"key":"2021111619381175600_B2","first-page":"2011","article-title":"Update on pathology of retinoblastoma","volume":"11","author":"Singh","year":"2018","journal-title":"Int. J. Ophthalmol."},{"key":"2021111619381175600_B3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s12098-017-2395-0","article-title":"Retinoblastoma","volume":"84","author":"Rao","year":"2017","journal-title":"Indian J. Pediatr."},{"key":"2021111619381175600_B4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41388-017-0050-x","article-title":"The management of retinoblastoma","volume":"37","author":"Fabian","year":"2018","journal-title":"Oncogene"},{"key":"2021111619381175600_B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41433-018-0244-7","article-title":"Retinoblastoma in Asia","volume":"33","author":"Jain","year":"2019","journal-title":"Eye"},{"key":"2021111619381175600_B6","first-page":"778","article-title":"Spectrum of germline RB1 mutations and clinical manifestations in retinoblastoma patients from Thailand","volume":"24","author":"Rojanaporn","year":"2018","journal-title":"Mol. Vis."},{"key":"2021111619381175600_B7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.22608\/APO.201711","article-title":"Genetics and molecular diagnostics in retinoblastoma-an update","volume":"6","author":"Soliman","year":"2017","journal-title":"Asia Pac. J. Ophthalmol. (Phila.)"},{"key":"2021111619381175600_B8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13000-015-0415-9","article-title":"High expression of TAZ indicates a poor prognosis in retinoblastoma","volume":"10","author":"Zhang","year":"2015","journal-title":"Diagn. Pathol."},{"key":"2021111619381175600_B9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000495575","article-title":"Ginsenoside-Rg5 inhibits retinoblastoma proliferation and induces apoptosis through suppressing BCL2 expression","volume":"63","author":"Cui","year":"2018","journal-title":"Chemotherapy"},{"key":"2021111619381175600_B10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.17219\/acem\/70418","article-title":"Inhibition of migration and invasion by berberine via inactivation of PI3K\/Akt and p38 in human retinoblastoma cell line","volume":"27","author":"Wang","year":"2018","journal-title":"Adv. Clin. Exp. Med."},{"key":"2021111619381175600_B11","doi-asserted-by":"publisher","first-page":"pii:BSR20180076","DOI":"10.1042\/BSR20180776","article-title":"MiR-140-5p suppresses retinoblastoma cell growth via inhibiting c-Met\/AKT\/mTOR pathway","volume":"38","author":"Liao","year":"2018","journal-title":"Biosci. Rep."},{"key":"2021111619381175600_B12","first-page":"8257","article-title":"Highly expressed lncRNA FAL1 promotes the progression of gastric cancer by inhibiting PTEN","volume":"22","author":"Zhu","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2021111619381175600_B13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/iub.1886","article-title":"PlncRNA-1 is overexpressed in retinoblastoma and regulates retinoblastoma cell proliferation and motility through modulating CBR3","volume":"70","author":"Wang","year":"2018","journal-title":"IUBMB Life"},{"key":"2021111619381175600_B14","doi-asserted-by":"publisher","first-page":"pii:BSR20180558","DOI":"10.1042\/BSR20180558","article-title":"The silencing of long non-coding RNA ANRIL suppresses invasion, and promotes apoptosis of retinoblastoma cells through the ATM-E2F1 signaling pathway","volume":"38","author":"Yang","year":"2018","journal-title":"Biosci. Rep."},{"key":"2021111619381175600_B15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.biopha.2018.07.052","article-title":"LncRNA THOR acts as a retinoblastoma promoter through enhancing the combination of c-myc mRNA and IGF2BP1 protein","volume":"106","author":"Shang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"2021111619381175600_B16","doi-asserted-by":"publisher","first-page":"pii:BSR20180384","DOI":"10.1042\/BSR20180384","article-title":"LncRNA AFAP1-AS1 is a prognostic biomarker and serves as oncogenic role in retinoblastoma","volume":"38","author":"Hao","year":"2018","journal-title":"Biosci. Rep."},{"key":"2021111619381175600_B17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/iub.1880","article-title":"Long noncoding RNA FAL1 promotes proliferation and inhibits apoptosis of human colon cancer cells","volume":"70","author":"Wu","year":"2018","journal-title":"IUBMB Life"},{"key":"2021111619381175600_B18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.biopha.2017.08.057","article-title":"LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC)","volume":"95","author":"He","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"2021111619381175600_B19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.prp.2018.04.014","article-title":"Upregulation of LncRNA FEZF-AS1 is associated with advanced clinical stages and family history of cancer in patients with NSCLC","volume":"214","author":"Gong","year":"2018","journal-title":"Pathol. Res. Pract."},{"key":"2021111619381175600_B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3727\/096504018X15199482824130","article-title":"lncRNA FEZF1-AS1 is associated with prognosis in lung adenocarcinoma and promotes cell proliferation, migration, and invasion","volume":"27","author":"Liu","year":"2018","journal-title":"Oncol. Res."},{"key":"2021111619381175600_B21","doi-asserted-by":"publisher","first-page":"103004","DOI":"10.18632\/oncotarget.21265","article-title":"LincRNA FEZF1-AS1 contributes to the proliferation of LAD cells by silencing p57 expression","volume":"8","author":"Jin","year":"2017","journal-title":"Oncotarget"},{"key":"2021111619381175600_B22","doi-asserted-by":"publisher","first-page":"8630","DOI":"10.1002\/jcp.26611","article-title":"Long non-coding RNA FEZF1-AS1 promotes breast cancer stemness and tumorigenesis via targeting miR-30a\/Nanog axis","volume":"233","author":"Zhang","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"2021111619381175600_B23","first-page":"5614","article-title":"lncRNA FEZF1AS1 contributes to cell proliferation, migration and invasion by sponging miR4443 in hepatocellular carcinoma","volume":"18","author":"Gong","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"2021111619381175600_B24","doi-asserted-by":"publisher","first-page":"8481","DOI":"10.1002\/jcb.27074","article-title":"LncRNA FAL1 is a negative prognostic biomarker and exhibits pro-oncogenic function in osteosarcoma","volume":"119","author":"Wang","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"2021111619381175600_B25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-017-0588-9","article-title":"LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer"},{"key":"2021111619381175600_B26","doi-asserted-by":"crossref","first-page":"49201","DOI":"10.18632\/oncotarget.17329","article-title":"Identification of aberrantly expressed long non-coding RNAs in stomach adenocarcinoma","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"key":"2021111619381175600_B27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.biopha.2017.11.113","article-title":"Long noncoding RNA FEZF1-AS1 indicates a poor prognosis of gastric cancer and promotes tumorigenesis via activation of Wnt signaling pathway","volume":"96","author":"Wu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"2021111619381175600_B28","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.18632\/oncotarget.7168","article-title":"Long non-coding RNA FEZF1-AS1 facilitates cell proliferation and migration in colorectal carcinoma","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"2021111619381175600_B29","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1158\/1078-0432.CCR-17-2967","article-title":"LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling","volume":"24","author":"Bian","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"2021111619381175600_B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41419-017-0052-1","article-title":"FEZF1-AS1\/miR-107\/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma","volume":"9","author":"Ye","year":"2018","journal-title":"Cell Death Dis."},{"key":"2021111619381175600_B31","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28188","article-title":"Long noncoding RNA FEZF1-AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miR-142\/HIF-1alpha and miR-133a\/EGFR upon hypoxia\/normoxia","author":"Ou","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"2021111619381175600_B32","doi-asserted-by":"publisher","first-page":"8088","DOI":"10.12659\/MSM.911194","article-title":"Long noncoding RNA FEZF1-AS1 promotes proliferation and inhibits apoptosis in ovarian cancer by activation of JAK-STAT3 pathway","volume":"24","author":"Zhao","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"2021111619381175600_B33","first-page":"3357","article-title":"Long non-coding RNA FEZF1-AS1 is up-regulated and associated with poor prognosis in patients with cervical cancer","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2021111619381175600_B34","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3727\/096504018X15188367859402","article-title":"Long non-coding RNA FEZF1-AS1 promotes osteosarcoma progression by regulating miR-4443\/NUPR1 axis","volume":"26","author":"Zhou","year":"2018","journal-title":"Oncol. Res."},{"key":"2021111619381175600_B35","doi-asserted-by":"publisher","first-page":"pii:BSR20180906","DOI":"10.1042\/BSR20180906","article-title":"FEZF1-AS1 is a key regulator of cell cycle, epithelial-mesenchymal transition and Wnt\/beta-catenin signaling in nasopharyngeal carcinoma cells","volume":"39","author":"Cheng","year":"2019","journal-title":"Biosci. Rep."},{"key":"2021111619381175600_B36","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/j.biopha.2018.04.094","article-title":"Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610\/Akt3 axis","volume":"103","author":"Li","year":"2018","journal-title":"Biomed. Pharmacother."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20190754\/848217\/bsr-2019-0754.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20190754\/848217\/bsr-2019-0754.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:26:24Z","timestamp":1637094384000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/39\/5\/BSR20190754\/219192\/FEZF1-AS1-functions-as-an-oncogenic-lncRNA-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20190754","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,5]]},"article-number":"BSR20190754"}}